27 related articles for article (PubMed ID: 23244100)
1. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.
Kim SJ; Rosen B; Fan I; Ivanova A; McLaughlin JR; Risch H; Narod SA; Kotsopoulos J
Br J Cancer; 2017 Mar; 116(7):964-971. PubMed ID: 28208158
[TBL] [Abstract][Full Text] [Related]
2. The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma.
Cheng XD; Lu WG; Ye F; Wan XY; Xie X
J Exp Clin Cancer Res; 2009 Jun; 28(1):91. PubMed ID: 19563645
[TBL] [Abstract][Full Text] [Related]
3. Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.
Alam S; Giri PK
Cancer Drug Resist; 2024; 7():6. PubMed ID: 38434767
[TBL] [Abstract][Full Text] [Related]
4. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities.
Ovejero-Sánchez M; González-Sarmiento R; Herrero AB
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672401
[TBL] [Abstract][Full Text] [Related]
5. Understanding Role of DNA Repair and Cytochrome p-450 Gene Polymorphisms in Cervical Cancer Patient Treated With Concomitant Chemoradiation.
Abbas M; Kushwaha VS; Srivastava K; Banerjee M
Br J Biomed Sci; 2022; 79():10120. PubMed ID: 35996502
[No Abstract] [Full Text] [Related]
6. DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
Tomasova K; Cumova A; Seborova K; Horak J; Koucka K; Vodickova L; Vaclavikova R; Vodicka P
Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32605254
[TBL] [Abstract][Full Text] [Related]
7. DNA damage repair in ovarian cancer: unlocking the heterogeneity.
Gee ME; Faraahi Z; McCormick A; Edmondson RJ
J Ovarian Res; 2018 Jun; 11(1):50. PubMed ID: 29925418
[TBL] [Abstract][Full Text] [Related]
8. Single nucleotide polymorphisms (SNPs) of hOGG1 and XRCC1 DNA repair genes and the risk of ovarian cancer in Polish women.
Michalska MM; Samulak D; Romanowicz H; Bieńkiewicz J; Sobkowski M; Ciesielski K; Smolarz B
Tumour Biol; 2015 Dec; 36(12):9457-63. PubMed ID: 26124010
[TBL] [Abstract][Full Text] [Related]
9. Identification of XRCC1 Arg399Gln and XRCC3 Thr241Met Polymorphisms in a Turkish Population and Their Association with the Risk of Chronic Lymphocytic Leukemia.
Mutlu P; Elçi MP; Yıldırım M; Nevruz O; Çetin AT; Avcu F
Indian J Hematol Blood Transfus; 2015 Sep; 31(3):332-8. PubMed ID: 26085717
[TBL] [Abstract][Full Text] [Related]
10. Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
Roco A; Cayún J; Contreras S; Stojanova J; Quiñones L
Front Genet; 2014; 5():391. PubMed ID: 25452763
[TBL] [Abstract][Full Text] [Related]
11. Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.
Li K; Li W
Mol Cell Biochem; 2013 Jan; 372(1-2):27-33. PubMed ID: 22983827
[TBL] [Abstract][Full Text] [Related]
12. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
Zhao D; Wu LY; Wang XB; Li XG
Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
[TBL] [Abstract][Full Text] [Related]
13. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
Przybylowska-Sygut K; Stanczyk M; Kusinska R; Kordek R; Majsterek I
Clin Breast Cancer; 2013 Feb; 13(1):61-8. PubMed ID: 23103366
[TBL] [Abstract][Full Text] [Related]
14. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis.
Zhang Z; Xiang Q; Mu G; Xie Q; Chen S; Zhou S; Hu K; Cui YM
Medicine (Baltimore); 2018 Nov; 97(45):e12996. PubMed ID: 30407287
[TBL] [Abstract][Full Text] [Related]
15. Prediction value of XRCC 1 gene polymorphism on the survival of ovarian cancer treated by adjuvant chemotherapy.
Miao J; Zhang X; Tang QL; Wang XY; Kai L
Asian Pac J Cancer Prev; 2012; 13(10):5007-10. PubMed ID: 23244100
[TBL] [Abstract][Full Text] [Related]
16. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Liblab S; Vusuratana A; Areepium N
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
